Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

After consideration of all of the comments (attached as appendix A) from a written consultation and stakeholder workshop on the initial review proposal where the Institute proposed to develop an implementation tool that allows the recommendations from TA160, 161 and 204 to be expressed in line with the recommendations for risk assessment in CG146, without a full review of the evidence for bisphosphonates, raloxifene or teriparatide in post-menopausal women and to combine this with the recently referred appraisal of drugs for osteoporosis treatment in men, the Institute’s Guidance Executive has decided to:

1. Appraise all relevant bisphosphonates licensed for the prevention of osteoporotic fragility fractures in women and men as an MTA, and that this should be given priority in scheduling
2. Appraise all non-bisphosphonates licensed for the prevention of osteoporotic fragility fractures in women and men as an MTA which will be scheduled to begin when the MTA on bisphosphonates has published its final appraisal determination.

Therefore these appraisals will be scheduled into technology appraisals work programme as Multiple Technology Appraisals (MTA).

March 2014